Amicus Therapeutics Inc. (NASDAQ:FOLD) shares saw unusually-high trading volume on Wednesday . Approximately 2,001,038 shares changed hands during trading, a decline of 14% from the previous session’s volume of 2,319,506 shares.The stock last traded at $5.79 and had previously closed at $6.00.

FOLD has been the subject of several research analyst reports. Goldman Sachs Group Inc. initiated coverage on Amicus Therapeutics in a research report on Wednesday, March 30th. They set a “neutral” rating and a $10.00 price objective for the company. Robert W. Baird initiated coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They set a “neutral” rating and a $9.00 price objective for the company. Bank of America Corp. initiated coverage on Amicus Therapeutics in a research report on Wednesday, May 18th. They set a “buy” rating and a $10.00 price objective for the company. Leerink Swann reissued an “outperform” rating and set a $19.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Finally, Chardan Capital boosted their price objective on Amicus Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, April 12th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.88.

The company’s market cap is $735.61 million. The firm’s 50 day moving average is $6.20 and its 200-day moving average is $7.04.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. Equities research analysts predict that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.

In related news, General Counsel Ellen Rosenberg acquired 15,000 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The stock was bought at an average price of $7.67 per share, for a total transaction of $115,050.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

A number of institutional investors have bought and sold shares of the company. Nationwide Fund Advisors boosted its position in Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,754 shares during the last quarter. ProShare Advisors LLC boosted its position in Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 15,789 shares during the last quarter. Swiss National Bank boosted its position in Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 5,100 shares during the last quarter. TD Asset Management Inc. boosted its position in Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock worth $1,733,000 after buying an additional 2,600 shares during the last quarter. Finally, Columbus Circle Investors boosted its position in Amicus Therapeutics by 122.7% in the fourth quarter. Columbus Circle Investors now owns 227,889 shares of the biopharmaceutical company’s stock worth $2,211,000 after buying an additional 125,574 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.